Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia

Journal of Chemotherapy

Volumn 20, Issue 6, 2008, Pages 714-720

  Garey, Kevin W ^a,b   Vo, Q P ^a   Larocco, M T ^b   Gentry, L O ^b   Tam, V H ^a,b  

^a UNIVERSITY OF HOUSTON   (United States)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Antibiotic susceptibility; Bacteremia; Epidemiology; Pseudomonas aeruginosa; Type III secretions proteins

Indexed keywords

AMIKACIN; BACTERIAL PROTEIN; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; PROTEIN EXOS; PROTEIN EXOU; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; FEMALE; GENE IDENTIFICATION; GRAM NEGATIVE SEPSIS; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA;

EID: 59349109012     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.6.714     Document Type: Article

References (35)

1. Jarvis WR, Martone WJ. Predominant pathogens in hospital infections. J Antimicrob Chemother 1992;29 Suppl A:19-24.
2. Bisbe J, Gatell JM, Puig J, et al. Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes. Rev Infect Dis 1988;10(3):629-35.
3. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989;87(5):540-6.
4. Gallagher PG, Watanakunakorn C. Pseudomonas bacteremia in a community teaching hospital, 1980-1984. Rev Infect Dis 1989;11(6):846-52.
5. Mallolas J, Gatell JM, Miro JM, et al. Analysis of prognostic factors in 274 consecutive episodes of Pseudomonas aeruginosa bacteremia. Antibiot Chemother 1991;44:106-14.
6. Mallolas J, Gatell JM, Miro JM, Marco F, Soriano E. Epidemiologic characteristics and factors influencing the outcome of Pseudomonas aeruginosa bacteremia. Rev Infect Dis 1990;12(4):718-9.
7. Roche O, Beuhorry-Sassus F, Boillot A, et al. Pseudomonas aeruginosa septicemia. Host-related risk factors in 82 episodes]. Presse Med 1995;24(25):1164-6.
8. Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 1996;156(18):2121-6.
9. Siegman-Igra Y, Ravona R, Primerman H, Giladi M. Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Int J Infect Dis 1998;2(4):211-5.
10. Kuikka A, Valtonen VV. Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis 1998;17(10):701-8.
11. Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes. Arch Intern Med 2000;160(4):501-9.
12. Pankhaniya RR, Tamura M, Allmond LR, et al. Pseudomonas aeruginosa causes acute lung injury via the catalytic activity of the patatin-like phospholipase domain of ExoU. Crit Care Med 2004;32(11):2293-9.
13. Shaver CM, Hauser AR. Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung. Infect Immun 2004;72(12):6969-77.
14. Ma Q, Zhai Y, Schneider JC, Ramseier TM, Saier MH, Jr. Protein secretion systems of Pseudomonas aeruginosa and P fluorescens. Biochim Biophys Acta 2003;1611(1-2):223-33.
15. Nguyen L, Paulsen IT, Tchieu J, Hueck CJ, Saier MH, Jr. Phylogenetic analyses of the constituents of Type III protein secretion systems. J Mol Microbiol Biotechnol 2000;2(2):125-44.
16. Hueck CJ. Type III protein secretion systems in bacterial pathogens of animals and plants. Microbiol Mol Biol Rev 1998;62(2):379-433.
17. Yahr TL, Mende-Mueller LM, Friese MB, Frank DW. Identification of type III secreted products of the Pseudomonas aeruginosa exoenzyme S regulon. J Bacteriol 1997; 179 (22): 7165-8.
18. Yahr TL, Vallis AJ, Hancock MK, Barbieri JT, Frank DW. ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system. Proc Natl Acad Sci U S A 1998; 95 (23): 13899-904.
19. Feltman H, Schulert G, Khan S, Jain M, Peterson L, Hauser AR. Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology 2001; 147 (Pt 10): 2659-69.
20. Vance RE, Rietsch A, Mekalanos JJ. Role of the type III secreted exoenzymes S, T, and Y in systemic spread of Pseudomonas aeruginosa PAO1 in vivo. Infect Immun 2005; 73(3): 1706-13.
21. Schulert GS, Feltman H, Rabin SD, et al. Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. J Infect Dis 2003; 188(11): 1695-706.
22. Hauser AR, Cobb E, Bodi M, et al. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 2002;30(3):521-8.
23. Roy-Burman A, Savel RH, Racine S, et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 2001;183(12):1767-74.
24. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of blood-stream infections on patient outcomes in the ICU setting. Chest 2000;118(1):146-55.
25. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115(2):462-74.
26. Harrington SM, Bishai WR. Chapter 8. Molecular epidemiology and infectious diseases. In: Nelson KE, Williams CM, Graham CMH, eds. Infectious disease epidemiology Theory and Practice. 1st ed: Aspen Publishers, Gaithersburg, MD; 2001:205-30.
27. Tam VH, Chang KT, Larocco MT, et al. Prevalence, mechanisms, and risk factors of carbapenem resistance in blood-stream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2007; 58(3): 309-14.
28. Syrmis MW, O'Carroll MR, Sloots TP, et al. Rapid genotyping of Pseudomonas aeruginosa isolates harboured by adult and paediatric patients with cystic fibrosis using repetitive-element-based PCR assays. J Med Microbiol 2004;53(Pt 11): 1089-96.
29. Berthelot P, Attree I, Plesiat P, et al. Genotypic and phenotypic analysis of type III secretion system in a cohort of Pseudomonas aeruginosa bacteremia isolates: evidence for a possible association between O serotypes and exo genes. J Infect Dis 2003;188(4):512-8.
30. Ferrer M, Ioanas M, Arancibia. F, Marco MA, de la Bellacasa JP, Torres A. Microbial airway colonization is associated with noninvasive ventilation failure in exacerbation of chronic obstructive pulmonary disease. Crit Care Med 2005;33(9):2003-9.
31. Thuong M, Arvaniti K, Ruimy R, et al. Epidemiology of Pseudomonas aeruginosa and risk factors for carriage acquisition in an intensive care unit. J Hosp Infect 2003;53(4):274-82.
32. Zhu H, Conibear TC, Bandara R, Aliwarga Y, Stapleton F, Willcox MD. Type III secretion system-associated toxins, proteases, serotypes, and antibiotic resistance of Pseudomonas aeruginosa isolates associated with keratitis. Curr Eye Res 2006;31(4):297-306.
33. Holder IA, Neely AN, Frank DW. PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice. Infect Immun 2001;69(9):5908-10.
34. Sawa T, Yahr TL, Ohara M, et al. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med 1999;5(4):392-8.
35. Joly B, Pierre M, Auvin S, et al. Relative expression of Pseudomonas aeruginosa virulence genes analyzed by a real time RT-PCR method during lung infection in rats. FEMS Microbiol Lett 2005;243(1):271-8.